<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medinfo</journal-id><journal-title-group><journal-title xml:lang="ru">Актуальные проблемы теоретической и клинической медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Actual Problems of Theoretical and Clinical Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2790-1289</issn><issn pub-type="epub">2790-1297</issn><publisher><publisher-name>Казахстанско-Российский медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24412/2790-1289-2023-1-21-27</article-id><article-id custom-type="elpub" pub-id-type="custom">medinfo-286</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>ПРОГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ КЛИНИКО- МОРФОЛОГИЧЕСКИХ ФАКТОРОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ В РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ</article-title><trans-title-group xml:lang="en"><trans-title>PROGNOSTIC VALUE OF CLINICAL AND MORPHOLOGICAL FACTORS OF BREAS T CANCER IN REAL CLINICAL PRACTICE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7087-1440</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Есентаева</surname><given-names>С. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Yessentayeva</surname><given-names>S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Есентаева Сурия Ертугуровна, доктор медицинских наук, доцент</p><p>Алматы</p></bio><bio xml:lang="en"><p>Yessentayeva Suriya, MD, Associate Professor</p><p>Almaty</p></bio><email xlink:type="simple">s.esentaeva@medkrmu.kz</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абылгазиева</surname><given-names>А. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Abylgazieva</surname><given-names>A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алматы</p></bio><bio xml:lang="en"><p>Aidana Abylgazieva</p><p>Almaty</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Айдаров</surname><given-names>Д. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Aidarov</surname><given-names>D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алматы</p></bio><bio xml:lang="en"><p>Daulet Aidarov</p><p>Almaty</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сарсенбаева</surname><given-names>Г. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Sarsenbayeva</surname><given-names>G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алматы</p></bio><bio xml:lang="en"><p>Galiya Sarsenbayeva</p><p>Almaty</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бейсебаев</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Beisebaev</surname><given-names>E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алматы</p></bio><bio xml:lang="en"><p>Eldar Beisebaev</p><p>Almaty</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">НУО «Казахстанско-Российский медицинский университет»<country>Казахстан</country></aff><aff xml:lang="en">NEI «Kazakh-Russian Medical University»<country>Kazakhstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>27</day><month>04</month><year>2023</year></pub-date><volume>0</volume><issue>1</issue><fpage>21</fpage><lpage>27</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Есентаева С.Е., Абылгазиева А.Б., Айдаров Д.Е., Сарсенбаева Г.Е., Бейсебаев Е.Н., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Есентаева С.Е., Абылгазиева А.Б., Айдаров Д.Е., Сарсенбаева Г.Е., Бейсебаев Е.Н.</copyright-holder><copyright-holder xml:lang="en">Yessentayeva S., Abylgazieva A., Aidarov D., Sarsenbayeva G., Beisebaev E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://kazrosmedjournal.krmu.edu.kz/jour/article/view/286">https://kazrosmedjournal.krmu.edu.kz/jour/article/view/286</self-uri><abstract><p>В настоящей статье мы представляем материал ретроспективного анализа по частоте встречаемости и прогностической роли некоторых морфологических маркеров (tumor infiltrating lymphocytes (TILs), опухолевые эмболы в стенках сосудов, инвазия в стенки сосудов) у пациенток впервые установленным диагнозом рак молочной железы (РМЖ), получивших лечение в условиях Алматинской региональной многопрофильной клиники (АРМК), в зависимости от возраста, стадии заболевания и фенотипа опухоли.</p></abstract><trans-abstract xml:lang="en"><p>In this article, we present the material of a retrospective analysis of the frequency of occurrence and prognostic role of certain morphological markers (tumor infiltrating lymphocytes (TILs), tumor emboli in the walls of vessels, invasion into the walls of vessels) in patients with a newly diagnosed breast cancer (breast cancer) who received treatment in the conditions of the Almaty regional Multidisciplinary Clinic (ARMK), depending on the age, stage of the disease and the phenotype of the tumor.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>TILs</kwd><kwd>опухолевые эмболы</kwd><kwd>инвазия в стенки сосудов</kwd><kwd>безрецидивная выживаемость</kwd><kwd>морфологические маркеры</kwd></kwd-group><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>TILs</kwd><kwd>tumor emboli</kwd><kwd>invasion of vascular walls</kwd><kwd>relapse-free survival</kwd><kwd>morphological markers</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Киселевский М.В., Власенко Р.Я., Заботина Т.Н., Кадагидзе З.Г. Прогностическая значимость опухоль-инфильтрирующих лимфоцитов. Иммунология. 2019; 40 (1): 74 – 83. doi: 10.24411/0206-4952-2019-11009.</mixed-citation><mixed-citation xml:lang="en">Kiselevskiy M.V., Vlasenko R.Ya., Zabotina T.N., Kadagidze Z.G. Prognostic significance of tumor-infiltrating lymphocytes. Immunology. 2019; 40 (1): 74–83. doi: 10.24411/0206-4952-2019-11009.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Семиглазов В.Ф., Целуйко А.И., Донских Р.В. и др. Иммунология и иммунотерапия рака молочной железы // Эффективная фармакотерапия. 2020. Т. 16. № 11. С. 46 – 51. DOI 10.33978/2307-3586-2020-16-11-46-51.</mixed-citation><mixed-citation xml:lang="en">Semiglazov V.F., Tseluyko A.I., Donskikh R.V. et al. Immunology and immunotherapy of breast cancer // Effective pharmacotherapy. 2020. T. 16. № 11. S. 46–51. DOI 10.33978/2307-3586-2020-16-11-46-51.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Семиглазов В.Ф., Криворотько П.В., Семиглазов В.В. и др. Иммунология рака молочной железы. М.: СИМК, 2019.</mixed-citation><mixed-citation xml:lang="en">Semiglazov V.F., Krivorot'ko P.V., Semiglazov V.V. et al. Immunology of breast cancer. M.: SIMK, 2019.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Denkert C., Loibl S., Noske A., Roller M., Muller B.M., Komor M., Budczies J., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 2010; 28 (1):105-113. https//doi.org/10.1200/JCO.2009.23.7370.</mixed-citation><mixed-citation xml:lang="en">Denkert C., Loibl S., Noske A., Roller M., Muller B.M., Komor M., Budczies J., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 2010; 28 (1):105-113. https//doi.org/10.1200/JCO.2009.23.7370.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Denkert C., von Mickwitz G., Brafе J. et al. Tumorinfiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers // J. Clin. Oncol. 2015. Vol. 33. № 9. P. 983 – 991.</mixed-citation><mixed-citation xml:lang="en">Denkert C., von Mickwitz G., Brafе J. et al. Tumorinfiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers // J. Clin. Oncol. 2015. Vol. 33. № 9. P. 983 – 991.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Dieci M.V., Mathieu M.C., Guarneri V. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials // Ann. Oncol. 2015. Vol. 26. № 8. P. 1698 – 1704.</mixed-citation><mixed-citation xml:lang="en">Dieci M.V., Mathieu M.C., Guarneri V. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials // Ann. Oncol. 2015. Vol. 26. № 8. P. 1698 – 1704.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Loi S., Michiels S., Salgado R. et al. Tumor-infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial // Ann. Oncol. 2014. Vol. 25. № 8. P. 1544–1550</mixed-citation><mixed-citation xml:lang="en">Loi S., Michiels S., Salgado R. et al. Tumor-infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial // Ann. Oncol. 2014. Vol. 25. № 8. P. 1544–1550</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Смирнова О.В., Борисов В.И. Иммунотерапия в лекарственном лечении больных с метастатическим тройным негативным раком молочной железы. Онкология. Журнал им. П.А. Герцена. 2018; 7 (6): 60 – 66.</mixed-citation><mixed-citation xml:lang="en">Smirnova O.V., Borisov V.I. Borisov V.I. Immunotherapy in the drug treatment of patients with metastatic triple negative breast cancer. Oncology. Magazine named after P.A. Gertsena. 2018; 7(6):60 66.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Loi S., Sirtaine N., Piette F., Salgado R., Viale G., Van Eenoo F., et al. Prognostic and predictive value of tumorinfiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node - positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02 - 98. J. Clin. Oncol. 2013; 31 (7): 860-867. https//doi.org/10.1200/JCO.2011.41.0902.</mixed-citation><mixed-citation xml:lang="en">Loi S., Sirtaine N., Piette F., Salgado R., Viale G., Van Eenoo F., et al. Prognostic and predictive value of tumorinfiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node - positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02 - 98. J. Clin. Oncol. 2013; 31 (7): 860-867. https//doi.org/10.1200/JCO.2011.41.0902.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Adams S., Gray R.J., Demaria S., Goldstein L., Perez E.A., Shulman L.N., et al. Prognostic value of tumorinfiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J.Clin. Oncol. 2014; 32 (27): 2959 - 2966. https//doi.org/10.1200/JCO.2013.55.0491.</mixed-citation><mixed-citation xml:lang="en">Adams S., Gray R.J., Demaria S., Goldstein L., Perez E.A., Shulman L.N., et al. Prognostic value of tumorinfiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J.Clin. Oncol. 2014; 32 (27): 2959 - 2966. https//doi.org/10.1200/JCO.2013.55.0491.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Disis M.L., Stanton S.E. Triple-negative breast cancer: immune modulation as the new treatment paradigm. Am. Soc. Clin. Oncol. Educ. Book. 2015:e25 - 30. doi: 10.14694/EdBook_AM.2015.35.e25. PMID: 25993181.</mixed-citation><mixed-citation xml:lang="en">Disis M.L., Stanton S.E. Triple-negative breast cancer: immune modulation as the new treatment paradigm. Am. Soc. Clin. Oncol. Educ. Book. 2015:e25 - 30. doi: 10.14694/EdBook_AM.2015.35.e25. PMID: 25993181.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Smid M., Hoes M., Sieuwerts A.M. et al. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes // Breast Cancer Res. Treat. 2011. Vol. 128. № 1. P. 23 – 30.</mixed-citation><mixed-citation xml:lang="en">Smid M., Hoes M., Sieuwerts A.M. et al. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes // Breast Cancer Res. Treat. 2011. Vol. 128. № 1. P. 23 – 30.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
